INTRODUCTION
Infections caused by methicillin-resistant Ceftaroline fosamil, a prodrug, is converted to the active form of ceftaroline via serum phosphatases and undergoes minimal cytochrome P450 oxidation. Approximately 88% of a dose of ceftaroline is excreted renally, with only 6% of the drug recovered in the feces [4] . The prescribing information indicates the approved dose of ceftaroline fosamil administered intravenously is 600 mg every 12 h for ABSSSI and CABP [7] . However, due to the increased volume of distribution (V d ), renal clearance, and urine output in burn injury patients, the patient's regimen was empirically modified to 600 mg IV every 8 h, and administered as a 2-h infusion to ensure that adequate drug concentrations be maintained throughout the dosing interval. Table 2) .
Serum Drug Assay and PK Characterization
The ceftaroline bioassay was performed according to previously published methods [8] .
Briefly, quarter-inch disks were placed on agar plates (antibiotic medium number 11) pre-swabbed with Bacillus subtilis ATCC 6633.
The disks were spotted with 10 lL of ceftaroline standards (2.5, 10, and 40 mg/L) or plasma samples. Each standard and sample was tested in duplicate. Plates were incubated for 18-24 h at 37°C, after which the zone sizes were measured using a protocol reader (Protocol; Microbiology International, Frederick, MD, USA). Ceftaroline half-life, C max (peak), and C min (trough) mg/L were determined from concentration-versus-time plots assuming a one-compartment model (Table 2) . Patient-specific concentrations and time above MIC (T[MIC) were calculated utilizing first-order elimination concepts ( Table 3 ). The elimination half-life, peak and trough concentrations, and area under the curve (AUC) were calculated using PK Analyst Software (version 1.10; MicroMath Scientific Software, Salt Lake City, UT, USA).
DISCUSSION
MRSA is a frequently encountered pathogen in burn units and poses a serious health risk. As aforementioned, this risk is not limited to burn site infections but can be associated with bacteremia and pneumonia. Due to the severity of burn injuries, patients may require multiple surgical procedures, numerous invasive central catheters, and prolonged periods of mechanical ventilation. These risk factors, in addition to the decreased immunological response, can dramatically increase the mortality rates in burn patients. Treatment of these infections in this patient population can present a PK challenge for clinicians, and patients frequently require high Table 3 Patient-specific ceftaroline PK parameters versus package insert It should be noted that the AUC 0-s for the burn patient is for 0-8 and 0-12 h per the package insert (i.e., the dosing interval) AUC area under the curve, C max maximum serum concentration, C min minimum serum concentration, MIC mean inhibitory concentration, T half-life, V d volume of distribution doses of antimicrobials to maintain adequate serum concentrations [9] [10] [11] [12] [13] [14] .
Patients that suffer from a thermal injury have numerous pathophysiological changes, which can dramatically alter the PK/PD of prescribed medications. The physiological changes vary based on the time elapsed from the initial burn injury. The acute phase occurs within the first 72 h of the burn injury and results in decreased cardiac and urine output, and increased systemic vascular resistance, which can affect the distribution and elimination of medications [15] . These alterations in cardiac output, renal clearance, and protein binding can significantly alter the PK properties of most medications including absorption, distribution, and elimination [15, 16] . The hypermetabolic phase occurs around 72 h after the burn injury. During this second phase of burn injury, patients will have increased levels of catecholamines, prostaglandins, glucagon, and cortisol which result in increased cardiac output and glomerular filtration rates [15] . Decreased albumin and increased acute-phase proteins resulting from the acute injury can also potentially alter the effectiveness of highly protein bound drug molecules since only free drug is available to elicit an effect [15, 16] .
Additionally, the V d in significantly burned patients ([20% total BSA), or patients with an inhalation injury, can be altered due to extensive fluid loss from the burned tissue [16] . Finally, hepatic metabolism of medications varies after a burn injury [12, 13, 15, 16] . In the hypermetabolic phase, a decrease in phase 1 metabolism can increase the half-life of medications that are hepatically metabolized and cleared, which ultimately increases the risk of toxicity to the patient. However, phase 2 metabolism, or glucuronidation, does not appear to be affected during the hypermetabolic phase of burn injury [17] .
Alterations in the physiological response to a burn make dosing medications, especially antibiotics, challenging in burn patients. Although not typically discussed in burn literature, an inhalation injury elicits the same physiological response as any other thermal injury [18] . Lovering and colleagues [19] evaluated the dosing regimens of linezolid in patients with [20% total BSA. In their study, the burn patients had increased non-renal clearance of the drug and elimination rate constants. However, the C max concentrations and the V d of linezolid were similar between the burn patients and healthy volunteers. A case report of a 27-year-old male with a 52% total BSA burn demonstrated that the typical dose of linezolid 600 mg IV every 12 h and meropenem 1 g IV every 8 h produced subtherapeutic serum concentrations in the patient, necessitating an increase in the frequency of dosing to obtain adequate concentrations of the antibiotics in serum, including T[MIC [20] . Daptomycin C max concentrations and AUC values have also been reported to be less (44% and 47%, respectively) in patients with thermal injury, with these patients experiencing a 77% increase in mean clearance values compared to healthy volunteers [12] . This study found that daptomycin doses would need to be increased to 10-12 mg/kg/dose to approximate drug exposures in healthy volunteers (dosed at 6 mg/kg/dose). Overall, the alterations in PK parameters in these antibiotics are variable based on burn size and renal function [16, 21] .
In one study evaluating cefepime, the renal clearance and V d were reportedly 10-30% higher in burn patients than non-burn patients [9] . As a result of available data in burn patients, the practice of increasing the dose, as well as the frequency of administration, may be reasonable to maintain therapeutic serum concentrations of antibiotics [9, 20, 21] .
In this case, alternative antimicrobial therapy was sought due to the patient's lack of clinical response to vancomycin therapy coupled with an elevated vancomycin MIC (2 mg/L). As previously mentioned, although literature supports linezolid in the treatment of nosocomial pneumonia, it was not chosen due to the potential for subtherapeutic concentrations resulting from pathophysiological changes. In addition, due to the patient's medication history, there was a potential for drug-drug interactions with the patient's prescribed antipsychotic medication, which included an SSRI and linezolid. Case reports have cautioned against the use of this combination as near-fatal serotonin syndrome has been reported with linezolid's inhibition of MAO-A and B [22] . Therefore, ceftaroline was initiated using the 600 mg dose at an 8-h dosing schedule, administered as a 2-h infusion, to maximize the PK/PD of the cephalosporin class (i.e., time-dependent killing) and allowing for infusion of other IV medications simultaneously. This dosing regimen has been studied in in vitro PK/PD models and shown to be highly effective against MRSA, while the 12-h regimen has been studied in complicated skin and skin structure infections and for treatment of CABP [23] [24] [25] [26] [27] . Bhavnani et al. [28] received an off-label dose. Side effects were noted to be slightly higher in these patients (17.1%) but all side effects reported in this study were noted to be B7.8% [30] . Although most patients in these reports received multiple agents active This ''inoculum effect'' has been noted with other beta-lactams, including cephalosporins as well as glycopeptide antimicrobials [32] [33] [34] . Our patient demonstrated similar drug clearance and V d compared to healthy adults. However, this patient also demonstrated a much shorter half-life (1.5 versus 2.66 h) and increased AUC (87.6 versus 56.3 lg h/mL), when compared with data reported in the ceftaroline prescribing information. This finding was dissimilar to previously published reports characterizing the increased clearance of beta-lactam antimicrobials in patients with thermal injury [9, 11, 14] . This could potentially be due to the limited amount of burn injury (\1% total BSA) and time period from the burn injury itself, as the ceftaroline therapy was initiated in this patient many days into their admission. Curiously, the concentration obtained 30-min post-infusion was higher than reported in the prescribing information and cannot be completely explained other than this patient exhibited altered ceftaroline PK distribution. The patient completed a total of 14 days of ceftaroline therapy and responded appropriately with resolution of signs and symptoms of infection, and more importantly with no reported toxicity from antimicrobial therapy. Ultimately, the patient was liberated from mechanical ventilation on HD 22 and discharged to a psychiatric care facility on HD 48.
CONCLUSION
In conclusion, we describe a case of an inhalational thermal burn injury patient successfully treated with ceftaroline 600 mg IV 
